Quick Answer
Decoy Therapeutics Inc. reported Diluted EPS of $129.10 per share (loss) for fiscal year 2025.
Decoy Therapeutics Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$129.10 | -85.6% |
| 2024 | -$69.54 | -126.2% |
| 2023 | -$30.74 | -106.6% |
| 2022 | -$14.88 | -92.7% |
| 2021 | -$7.72 | -1444.0% |
| 2020 | -$0.50 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.81 | +84.1% | -302.2% |
| June 30, 2025 | -$0.45 | +81.0% | +56.3% |
| March 31, 2025 | -$1.03 | +68.5% | +90.9% |
| September 30, 2024 | -$11.38 | -118.4% | -380.2% |
| June 30, 2024 | -$2.37 | +79.3% | +27.5% |
| March 31, 2024 | -$3.27 | -46.6% | +37.2% |
| September 30, 2023 | -$5.21 | +18.7% | +54.5% |
| June 30, 2023 | -$11.45 | -420.5% | -413.5% |
- Decoy Therapeutics Inc. showed a decrease of -85.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Decoy Therapeutics Inc.’s diluted eps has declined by 25720.0% (from $0.50 per share (loss) to $129.10 per share (loss)).
- The most recent figure is from Decoy Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: